Editorial:
Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer
Metrics: PDF 1360 views | ?
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27998